EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

High-Dose Walking Booster Program Is Feasible for People After Stroke: A Phase II Randomized Trial

Katharine Scrivener iD, Avanthi Elisha Ball, Catherine Dean, Joanne Glinsky, Louise Ada iD, Petra Graham iD, Johannah Campbell, Karen Felton, Natasha A Lannin iD

Stroke · 2026

DOI: 10.1161/strokeaha.125.051997 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2026. Verfasst von Katharine Scrivener und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Faculty of Medicine, Health and Human Sciences (K.S., A.E.B., C.D., J.C., K.F.), Macquarie University, Sydney, Austral…. Hauptthemen laut MEDLINE: Walking, Stroke Rehabilitation, Stroke, Exercise Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Maintaining walking ability in the long term after a stroke is challenging. Furthermore, access to ongoing physiotherapy is limited. This trial determined the feasibility of a clinical trial of a high-dose walking booster program (HiWalk) and measured clinical outcomes. METHODS: A multisite, assessor-blinded pilot and feasibility randomized trial was conducted in Australia (June 2023 to July 2024). Participants had a stroke 6 months to 8 years prior and could walk unaided at 0.4 m/s to 1.0 m/s. The experimental group received HiWalk plus usual care, while the control group received usual care alone. HiWalk was group-based motor training to improve walking, 43 hours over 3 weeks. Feasibility outcomes included recruitment and retention. Clinical outcomes included walking speed (preferred and fast over 5 m, fast over 6 minutes), and self-efficacy at 1 and 6 months. RESULTS: Eighty-two individuals were screened, and 47 participated: age 58 (SD, 16), time poststroke 2.7 years (SD, 2.1), and baseline fast walking speed 0.9 m/s (SD, 0.4). Feasibility outcomes: the HiWalk trial was feasible in terms of recruitment (refusal rate 27%), retention at 1 month (98%), adherence (mean 91% [SD 13] attendance once commenced), safety (minor adverse events 0.4/wk), and measurement (98% of data collected at 1 month). Clinical outcomes: at month 1, there was a beneficial effect on a 30-point self-efficacy scale (mean difference, 3.0 [95% CI, 0.1–5.9]). However, despite a small positive mean effect of HiWalk on fast walking speed (mean difference, 0.05 m/s [95% CI, −0.09 to 0.19]), there were no other significant between group differences. Exploratory analysis suggests the effect on walking speed for those not undertaking rehabilitation was 0.24 m/s (95% CI, 0.06–0.43) more than for those who were. CONCLUSIONS: The HiWalk booster program was a feasible way to deliver mobility training in the community after stroke. Benefits in clinical outcomes were found for the subgroup of participants no longer undertaking rehabilitation. Therefore, future research should target this subpopulation. REGISTRATION: URL: https://www.anzctr.org.au ; Unique identifier: ACTRN12623000316606.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WalkingStroke RehabilitationStrokeExercise TherapyHumansMaleFemaleMiddle AgedAgedFeasibility StudiesPilot ProjectsAustraliaTreatment OutcomeAdultSelf Efficacy

Stichwörter der Autor:innen

physical therapyrecovery of functionself efficacystrokewalking

Autor:innen und Institutionen

  • Department of Health Sciences, Faculty of Medicine, Health and Human Sciences (K.S., A.E.B., C.D., J.C., K.F.), Macquarie University, Sydney, Australia.
  • Department of Neurosciences, Monash University and Allied Health, Alfred Health, Melbourne, Australia (N.A.L., K.S.).
  • Discipline of Physiotherapy, Faculty of Medicine and Health, University of Sydney, Australia (J.G., L.A.).
  • School of Mathematical and Physical Sciences, Faculty of Science and Engineering (P.G.), Macquarie University, Sydney, Australia.

ORCID-Profile: Katharine Scrivener, Louise Ada, Petra Graham, Natasha A Lannin

Zitieren

APA

Scrivener, K., Ball, A. E., Dean, C., Glinsky, J., Ada, L., Graham, P., Campbell, J., Felton, K., & Lannin, N. A. (2026). High-Dose Walking Booster Program Is Feasible for People After Stroke: A Phase II Randomized Trial. Stroke. https://doi.org/10.1161/strokeaha.125.051997

Vancouver

Scrivener K, Ball AE, Dean C, Glinsky J, Ada L, Graham P, et al. High-Dose Walking Booster Program Is Feasible for People After Stroke: A Phase II Randomized Trial. Stroke. 2026. doi:10.1161/strokeaha.125.051997

BibTeX
@article{Scrivener2026,
  author = {Scrivener, Katharine and Ball, Avanthi Elisha and Dean, Catherine and Glinsky, Joanne and Ada, Louise and Graham, Petra and Campbell, Johannah and Felton, Karen and Lannin, Natasha A},
  title = {High-Dose Walking Booster Program Is Feasible for People After Stroke: A Phase II Randomized Trial},
  journal = {Stroke},
  year = {2026},
  doi = {10.1161/strokeaha.125.051997}
}
Kostenlos starten →